Compare Summit Therapeutics Inc (SMMT) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while T Rowe Price Group Inc trades at $105.16 (market cap $22.23B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.99% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and T Rowe Price Group Inc for 115 Days on average.
| SMMT | TROW | |
|---|---|---|
Market Cap | $13.71B | $22.23B |
Volume | 6,173,057 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $26.38 | $121.68 |
52-Week Low | $12.43 | $86.19 |
Typical Hold Time | 16 Days | 115 Days |
Enterprise Value | $13.04B | $19.43B |
Dividend Yield | — | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
T. Rowe Price Group (TROW) trades at $104.23, up 0.15% on the day, with a bearish technical signal but solid fundamentals. The stock shows consistent revenue growth, reaching $7.31B in 2025, and a strong net income margin of 29.26%. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 40-year dividend growth streak, paying $1.30 per share in H2 2026. Analyst consensus is mixed, with a $110.50 price target, but technical indicators point to near-term resistance at $105.
Outlook: TROW offers value with a low P/E of 10.46 and robust profitability, but faces headwinds from net outflows and bearish technicals. Investment opportunity lies in its dividend aristocrat status and earnings momentum, while risks include fee pressure from market volatility and competitive threats. The stock is a hold for income investors, with upside potential if operational trends improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
